February 01 2018 - Today, the International Generic and Biosimilar medicines Association (IGBA) launched an information campaign on biosimilar medicines. The foundation of this campaign is the IGBA biosimilar medicines public slide deck[1]. Access to well-referenced information is fundamental to improving worldwide understanding and acceptance of biosimilar medicines, which support patient access to life-saving treatments, enhance competition and contribute to healthcare system sustainability by offering savings for the same medical outcome.

January 29 2018 - The International Generic and Biosimilar medicines Association (IGBA) welcomes the Australian Government's decision to maintain the existing naming convention for biological, including biosimilar, medicines, that is to continue using the Australian biological name (without a specific identifier suffix) and to strengthen the adverse event reporting. This includes making the product's trade name, as well as the non-proprietary name, a mandatory field when reporting an adverse event to the Therapeutic Goods Administration (TGA).

2018-01-01 - The IGBA welcomes the Indian Pharmaceutical Alliance (IPA) to its membership. The IPA represents Indian research-based national pharmaceutical companies. This addition to the IGBA membership is significant in widening the IGBA representation, which now covers this important region.